Renal angiomyolipoma (AML) is a benign mesenchymal
soft tissue tumour that arises in the cortex or medulla of the kidney. AML is
considered “triphasic” in that it consists of adipose tissue, blood vessels,
and smooth muscle [1]. AML can arise sporadically or through an inherited
disorder. AML most commonly arises due to tuberous sclerosis compared to
sporadic [2]. The most dominant type of AML present in tuberous sclerosis is of
epithelioid origin.
Histologic fat
composition of the tumour allows a diagnosis of AML to be made readily by
abdominal CT or MRI [3]. Most sporadic AMLs are found incidentally, however in
a patient with tuberous sclerosis, a CT scan is ordered to look for potential
renal AMLs. AMLs may contain macroscopic or microscopic fat. In order to
distinguish between the two, an MRI may be ordered to assess for
fat-suppression. Due to their vascular nature, AMLs are prone to aneurysm
formation and rupture. Complications such as haemorrhage can result in a
symptomatic drop in haemoglobin and anaemia. Up to one-third of patients can
present with hypovolemic shock [4]. Symptomatic AMLs can present with Lenk’s
triad, which consists of flank pain, abdominal tenderness and internal
bleeding. Bleeding typically occurs when tumours are greater than 4 cm.
Patients are typically asymptomatic when tumours are less than 4 cm [5,6].
Traditional treatments of AML included nephrectomies or partial nephrectomies.
However, these therapeutic options are associated with significant
complications and risks [7]. Today, the preferential therapy is angiography
with selective arterial embolization [8].